Physician profile
Glenn S Prescod
NPI 1336263102
$3,842.79
in general payments reported to CMS, 2019-2025
21 companies · $752 in 2025
The $752 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $577 · 2021: $351 · 2022: $570 · 2023: $633 · 2024: $391 · 2025: $752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,221.79 | 2019-2025 | Constellation, Tryptyr, Rhopressa |
| Aerie Pharmaceuticals, INC. | $361.43 | 2019-2021 | |
| Astellas Pharma US INC | $340.56 | 2023-2025 | Izervay |
| Sun Pharmaceutical Industries INC. | $328.66 | 2021-2024 | Cequa |
| Genentech, INC. | $190.28 | 2022 | |
| New World Medical,INC. | $172.89 | 2022 | |
| Allergan, INC. | $148.75 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $127.55 | 2023 | Acthar |
| Immunocore Limited | $127.46 | 2025 | Kimmtrak |
| Astellas Pharma Global Development | $120.01 | 2025 | Izervay |
| Spark Therapeutics, INC. | $119.26 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $106.88 | 2019 | |
| Recordati_rare_diseases_inc. | $89.24 | 2024 | Cystadrops |
| Alexion Pharmaceuticals, INC. | $87.97 | 2022 | |
| Abbvie INC. | $87.73 | 2022-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $58.45 | 2021-2023 | Vabysmo |
| Amgen INC. | $50.00 | 2025 | Pavblu |
| Harrow Eye, LLC | $27.26 | 2025 | Iheezo |
| Mallinckrodt Enterprises LLC | $26.76 | 2019 | |
| Vanda Pharmaceuticals INC. | $24.97 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Prescod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.